Ultrasonic Package for Buchi Mini Spray Dryer S-300

The Food and Drug Administration’s Center for Drug Evaluation and Research is seeking an ultrasonic package to upgrade the Buchi Mini Spray Dryer S-300 and B-290 systems for advanced pharmaceutical manufacturing applications. The primary goal is to enable the production of spray-dried powders with particle sizes up to 60 microns, specifically tailored for intranasal drug delivery, which aligns with FDA’s broader research focus on enhancing drug quality, manufacturing reliability, and timely access to medicines. This technology supports the development of more consistent, robust, and scalable production processes critical to modern pharmaceutical innovation. The solicitation, identified as CDER-2026-133241, was posted on July 8, 2026, with responses due by July 20, 2026. It falls under NAICS code 334516 and is managed by the FDA under the Department of Health and Human Services, with performance expected in Silver Spring, Maryland. The primary point of contact is David Kramer, with Nick Sartain as the secondary contact, both reachable through FDA email addresses. No set-aside provisions apply, and the procurement is open to all eligible vendors capable of delivering the specified ultrasonic package compatible with the designated spray dryer models.